Repare Therapeutics (NASDAQ:RPTX) Releases Quarterly Earnings Results, Beats Expectations By $0.10 EPS

Repare Therapeutics (NASDAQ:RPTX) issued its quarterly earnings data on Monday. The company reported ($0.67) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.77) by $0.10, Zacks reports. Repare Therapeutics had a negative net margin of 99.76% and a negative return on equity of 40.87%.

Repare Therapeutics Stock Up 3.8 %

Repare Therapeutics stock traded up $0.05 during mid-day trading on Wednesday, hitting $1.22. 2,839 shares of the company’s stock were exchanged, compared to its average volume of 293,664. The company’s 50 day simple moving average is $1.26 and its 200-day simple moving average is $2.45. The firm has a market capitalization of $51.65 million, a P/E ratio of -0.61 and a beta of 0.87. Repare Therapeutics has a fifty-two week low of $1.06 and a fifty-two week high of $6.73.

Analyst Upgrades and Downgrades

A number of research firms have commented on RPTX. Stifel Nicolaus reduced their target price on Repare Therapeutics from $9.00 to $4.00 and set a “buy” rating on the stock in a report on Friday, December 13th. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Repare Therapeutics in a report on Friday, November 8th. Lifesci Capital reiterated a “market perform” rating on shares of Repare Therapeutics in a research report on Friday, December 13th. Finally, Bloom Burton lowered Repare Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 10th.

About Repare Therapeutics

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.